Gardner Lewis Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Gardner Lewis Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-653,711	Closed	-$22.5M	–	84
2020 Q3	$22.5M	Buy	+653,711	New	+$13.9M	4.08%	7

Gardner Lewis Asset Management's AIMT Position: Q4 2020 in Review

Gardner Lewis Asset Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 653,711 shares — an estimated $22.5M sold.

Gardner Lewis Asset Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $22.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Gardner Lewis Asset Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Gardner Lewis Asset Management sold 653,711 Aimmune Therapeutics shares in Q4 2020, an estimated $22.5M.
Gardner Lewis Asset Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Gardner Lewis Asset Management's Aimmune Therapeutics position peaked at $22.5M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Gardner Lewis Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.